|Articles|April 15, 2004

FDA expedites review of kidney cancer drug

The FDA has added BAY 43-9006, an investigational treatment for metastatic renal cell carcinoma, to its fast track program.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

September 18th, 2026

Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

September 18th, 2026

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

September 18th, 2026

A decision is expected by the fourth quarter of 2026.

September 17th, 2026

Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.

September 17th, 2026

Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC

September 17th, 2026

EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.

September 17th, 2026

Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.

September 16th, 2026

The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.